Abstract:Background/Introduction Marfan syndrome (MFS) is a hereditary connective tissue disorder caused by fibrillin-1 (FBN1) gene mutations. Life-threatening complications are cardiovascular, e.g. thoracic aortic aneurysms and dissections. The pathophysiological cause is the increased release of transforming growth factor β-1 (TGF-β1) from the FBN1-deficient extracellular matrix (ECM) and structural disintegrity. Overactivation of the mechanistic target of rapamycin (mTOR) pathway has been demonstrated in the murine mgR/mgR model of MFS. Short-term administration of rapamycin significantly reduced aortic aneurysm formation and increased the life span in these mice. Purpose To assess the effect of an early continuous oral low-dose rapamycin treatment on the aortic aneurysm formation in the FBN1 hypomorphic mgR/mgR mouse model. Methods Male and female 3-4 week-old mgR/mgR mice were orally administered vehicle or rapamycin through diet (8mg/kg/KG) and sacrificed after 11 weeks. Rapamycin concentration was measured by liquid chromatography-mass spectrometry in whole blood. Aortic diameter was studied using echocardiography. Histopathological and immunofluorescence analyses were performed using aortic tissue sections and techniques. Results Blood rapamycin concentration following oral administration remained below detection level. Rapamycin normalized the aortic wall thickness and the diameter in female mgR/mgR mice to levels of the littermate control mice but not in male mgR/mgR mice. The circumferentially distributed elastin fibres remained significantly intact in sections of the ascending aorta of female mice. Echocardiography revealed that rapamycin-treated female mice stayed below a cut-off value for aortic aneurysms of 2 mm inner aortic diameter eight weeks after starting therapy. In contrast, vehicle-treated female animals already exceeded this value after five weeks. In female but not in male mice, the abundance of the mTOR downstream target phosphorylated ribosomal protein S6 was effectively suppressed by low-dose rapamycin up to levels detected in control animals. At the same time, extracellular matrix proteins like the proteoglycan aggrecan (ACAN) and the related chondroitin sulfate were significantly decreased in female mice. The abundance of ADAMTS5 transglutaminase-2 and xylosyltransferase-1, key enzymes involved in the turnover of proteoglycans and biosynthesis of glycosaminoglycan chains, was improved by the rapamycin treatment in female mice. No decrease in mTOR activity could be detected in male mgR/mgR animals. Here, the ACAN and chondroitin sulphate levels also remained at the level of the vehicle-treated animals. Conclusions Chronic low-dose rapamycin treatment reduced aneurysm formation only in female mgR/mgR mice, since the dose was too low for male mgR/mgR mice, by affecting the composition and organization of key ECM components essential for maintaining aortic homeostasis and mechanical properties.

Impact of long-term rapamycin treatment on age-related osteoarthritis in common marmoset

The common marmoset as a translational model of age-related osteoarthritis

Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice

Rapamycin prevents early steps of the development of diabetic nephropathy in rats.

The mammalian target of rapamycin contributes to synovial fibroblast pathogenicity in rheumatoid arthritis

Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension.

Oral low-dose rapamycin treatment prevents aortic aneurysms in marfan mice

RICTOR-mediated Activation of AKT/mTOR Signaling and Autophagy Inhibition Promote Osteoarthritis.

Rapamycin Rescues Age-Related Changes in Muscle-Derived Stem/Progenitor Cells from Progeroid Mice

Targeting the biology of aging with mTOR inhibitors

Rapamycin reduces atherosclerotic plaque inflammation in aged mice

The Effect of Rapamycin on Bone Growth in Rabbits.

Rapamycin Reduces Arterial Mineral Density and Promotes Beneficial Vascular Remodeling in a Murine Model of Severe Medial Arterial Calcification

Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans

Effect of Chronic Administration of Low Dose Rapamycin on Development and Immunity in Young Rats

Protective Effect of Rapamycin against Mitochondrial Injury in an Aging Parkinson's Disease Mouse Model

Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results

Peripheral tissular analysis of rapamycin's effect as a neuroprotective agent in vivo

Rapamycin protects chondrocytes against IL-18-induced apoptosis and ameliorates rat osteoarthritis

Distinct and Additive Effects of Calorie Restriction and Rapamycin in Aging Skeletal Muscle

Effects of low-dose rapamycin on lymphoid organs of mice prone and resistant to accelerated senescence